Compare Cytokinetics Inc (CYTK) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Ross Stores, Inc. — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Ross Stores, Inc. trades at $226 (market cap $71.94B). The key difference: Ross Stores, Inc. is far larger — about 8.3× Cytokinetics Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Ross Stores, Inc. for 48 Days on average.
| CYTK | ROST | |
|---|---|---|
Market Cap | $8.62B | $71.94B |
Volume | 2,594,626 | 2,002,519 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $255.23 |
52-Week Low | $54.76 | $147.71 |
Typical Hold Time | 19 Days | 48 Days |
Enterprise Value | $8.72B | $72.39B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Ross Stores (ROST) trades at $225.53, up 0.59% today, with a bearish technical signal but strong fundamental performance. The stock shows robust profitability with a net income margin of 10.85% and ROE of 42.63%, supported by consistent earnings beats in recent quarters. Revenue growth trends upward, reaching $21.13B in 2025, while analyst consensus remains bullish with a $274.14 price target. Recent news highlights store expansion and value-focused strategies attracting shoppers amid competitive retail pressures.
The outlook for ROST is positive based on earnings momentum and strategic initiatives, though technical indicators suggest near-term caution. Risks include rising costs and market volatility, but institutional buying and high ROE provide support. The stock offers growth potential if execution on expansion continues, with downside cushioned by strong cash flow and analyst optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
